Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)

Samuel Q. Li; Adam T. Cheuk; Jack F. Shern; Young K. Song; Laura Hurd; Hongling Liao; Jun S. Wei; Javed Khan

doi:10.1371/journal.pone.0076551

Loading metrics

Open Access

Peer-reviewed

Research Article

Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)

Samuel Q. Li,

Affiliation Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Adam T. Cheuk,

Affiliation Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Jack F. Shern,

Affiliation Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Young K. Song,

Affiliation Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Laura Hurd,

Affiliation Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Hongling Liao,

Affiliation Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Jun S. Wei,

Affiliation Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Javed Khan

* E-mail: khanjav@mail.nih.gov

Affiliation Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯

Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)

Samuel Q. Li,
Adam T. Cheuk,
Jack F. Shern,
Young K. Song,
Laura Hurd,
Hongling Liao,
Jun S. Wei,
Javed Khan

Published: October 4, 2013
https://doi.org/10.1371/journal.pone.0076551

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Fibroblast growth factor
Is the Subject Area "Fibroblast growth factor" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Phosphorylation
Is the Subject Area "Phosphorylation" applicable to this article?

Thanks for your feedback.
Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.
Polymerase chain reaction
Is the Subject Area "Polymerase chain reaction" applicable to this article?

Thanks for your feedback.
Tyrosine kinases
Is the Subject Area "Tyrosine kinases" applicable to this article?

Thanks for your feedback.
Rhabdomyosarcoma
Is the Subject Area "Rhabdomyosarcoma" applicable to this article?

Thanks for your feedback.